{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:45:23Z","timestamp":1780598723853,"version":"3.54.1"},"posted":{"date-parts":[[2023,3,20]]},"group-title":"In Review","reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,2,8]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Objective:<\/bold> Recent advances in the understanding of neurodevelopmental disorders such as Rett syndrome (RTT) has enabled development of novel therapeutic approaches that are currently undergoing clinical evaluation or are proposed to move into clinical development. Clinical trial success depends on outcome measures that assess clinical features that are most impactful for affected individuals. To determine the top concerns in RTT and RTT-related disorders we asked caregivers to list the top clinical concerns in order to gain information to guide the development and selection of outcome measures for future clinical trials.\n<bold>Methods:<\/bold> Caregivers of participants enrolled in the US Natural History Study of RTT and related disorders were asked to identify the top 3 concerning problems impacting the affected participant. We generated a weighted list of top caregiver concerns for each of the diagnostic categories and compared results between the disorders. Further, for Classic RTT, caregiver concerns were analyzed by age, clinical severity, and common RTT-causing mutations in <italic>MECP2<\/italic>.\n<bold>Results:<\/bold> The top caregiver concerns for Classic RTT were effective communication, seizures, walking\/balance issues, lack of hand use, and constipation. The rank order of the frequency of the top caregiver concerns for Classic RTT varied by age, clinical severity, and specific mutations, consistent with known variation in the frequency of clinical features across these domains. The frequency of caregiver concern for seizures, hand use, and spoken language increased in relation to clinician assessed severity in these clinical domains, showing consistency between clinician assessments and caregiver concerns. Comparison across disorders found commonalities in the top caregiver concerns between Classic RTT, Atypical RTT, <italic>MECP2<\/italic> Duplication Syndrome, CDKL5 Deficiency Disorder, and FOXG1 Syndrome; however, distinct differences in caregiver concerns between these disorders are consistent with the relative prevalence and impact of specific clinical features.\n<bold>Conclusion:<\/bold> The top caregiver concerns for individuals with RTT and the RTT-related disorders reflect the impact of the primary clinical symptoms of these disorders. This work is critical in the development of meaningful therapies, as optimal therapy should address these concerns. Further, outcome measures to be utilized in clinical trials should assess these clinical issues identified as most concerning by caregivers.<\/p>","DOI":"10.21203\/rs.3.rs-2566253\/v1","type":"posted-content","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T22:14:37Z","timestamp":1679350477000},"source":"Crossref","is-referenced-by-count":7,"title":["Top Caregiver Concerns in Rett syndrome and related disorders: data from the US Natural History Study"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5628-5872","authenticated-orcid":false,"given":"Jeffrey Lorenz","family":"Neul","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Benke","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine: University of Colorado Anschutz Medical Campus School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[{"name":"Childrens Hospital of Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Suter","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Silveira","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine: University of Colorado Anschutz Medical Campus School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary","family":"Fu","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika U.","family":"Peters","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Percy","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rett syndrome Natural History Study","family":"Group","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajmg.b.32707","article-title":"The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2","volume":"180","author":"Neul JL","year":"2019","unstructured":"Neul JL, Benke TA, Marsh ED, Skinner SA, Merritt J, Lieberman DN, et al. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2. Am J Med Genet B Neuropsychiatr Genet. 2019;180(1):55\u201367.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"Neul JL","year":"2010","unstructured":"Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944\u201350.","journal-title":"Ann Neurol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"e000731","DOI":"10.1136\/bmjpo-2020-000731","article-title":"Multisystem comorbidities in classic Rett syndrome: a scoping review","volume":"4","author":"Fu C","year":"2020","unstructured":"Fu C, Armstrong D, Marsh E, Lieberman D, Motil K, Witt R, et al. Multisystem comorbidities in classic Rett syndrome: a scoping review. BMJ Paediatr Open. 2020;4(1):e000731.","journal-title":"BMJ Paediatr Open"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"e000717","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu C","year":"2020","unstructured":"Fu C, Armstrong D, Marsh E, Lieberman D, Motil K, Witt R, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open. 2020;4(1):e000717.","journal-title":"BMJ Paediatr Open"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pediatrneurol.2017.01.032","article-title":"Scoliosis in Rett Syndrome: Progression, Comorbidities, and Predictors","volume":"70","author":"Killian JT","year":"2017","unstructured":"Killian JT, Lane JB, Lee HS, Skinner SA, Kaufmann WE, Glaze DG, et al. Scoliosis in Rett Syndrome: Progression, Comorbidities, and Predictors. Pediatr Neurol. 2017;70:20\u20135.","journal-title":"Pediatr Neurol"},{"issue":"16","key":"ref6","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/01.wnl.0000291011.54508.aa","article-title":"Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome","volume":"70","author":"Neul JL","year":"2008","unstructured":"Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008;70(16):1313\u201321.","journal-title":"Neurology"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jmedgenet-2013-102113","article-title":"Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome","volume":"51","author":"Cuddapah VA","year":"2014","unstructured":"Cuddapah VA, Pillai RB, Shekar KV, Lane JB, Motil KJ, Skinner SA, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 2014;51(3):152\u20138.","journal-title":"J Med Genet"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1242\/dmm.011007","article-title":"Preclinical research in Rett syndrome: setting the foundation for translational success","volume":"5","author":"Katz DM","year":"2012","unstructured":"Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L, et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech. 2012;5(6):733\u201345.","journal-title":"Dis Model Mech"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1093\/hmg\/ddv030","article-title":"Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene","volume":"24","author":"Pitcher MR","year":"2015","unstructured":"Pitcher MR, Herrera JA, Buffington SA, Kochukov MY, Merritt JK, Fisher AR, et al. Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene. Hum Mol Genet. 2015;24(9):2662\u201372.","journal-title":"Hum Mol Genet"},{"key":"ref10","author":"Merritt JK","year":"2020","unstructured":"Merritt JK, Collins BE, Erickson KR, Dong H, Neul JL. Pharmacological readthrough of R294X Mecp2 in a novel mouse model of Rett Syndrome.Hum Mol Genet. 2020."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2147\/NDT.S371483","article-title":"Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage","volume":"18","author":"Collins BE","year":"2022","unstructured":"Collins BE, Neul JL. Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage. Neuropsychiatr Dis Treat. 2022;18:2813\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref12","first-page":"8","article-title":"Reversal of Neurological Defects in a Mouse Model of Rett Syndrome","volume":"8","author":"Guy J","year":"2007","unstructured":"Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of Neurological Defects in a Mouse Model of Rett Syndrome. Science. 2007;8:8.","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","article-title":"A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome","volume":"76","author":"Glaze DG","year":"2017","unstructured":"Glaze DG, Neul JL, Percy A, Feyma T, Beisang A, Yaroshinsky A, et al. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. Pediatr Neurol. 2017;76:37\u201346.","journal-title":"Pediatr Neurol"},{"issue":"16","key":"ref14","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze DG","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92(16):e1912\u2013e25.","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"106704","DOI":"10.1016\/j.cct.2022.106704","article-title":"Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome","volume":"114","author":"Neul JL","year":"2022","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Peters SU, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials. 2022;114:106704.","journal-title":"Contemp Clin Trials"},{"key":"ref16","author":"Louise S","year":"2009","unstructured":"Louise S, Fyfe S, Bebbington A, Bahi-Buisson N, Anderson A, Pineda M et al. InterRett, a model for international data collection in a rare genetic disorder.Res Autism Spectr Disord. 2009;3(3)."},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1177\/0883073815579707","article-title":"Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale","volume":"30","author":"Neul JL","year":"2015","unstructured":"Neul JL, Glaze DG, Percy AK, Feyma T, Beisang A, Dinh T, et al. Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale. J Child Neurol. 2015;30(13):1743\u20138.","journal-title":"J Child Neurol"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1352\/1944-7558-125.6.493","article-title":"A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials","volume":"125","author":"Raspa M","year":"2020","unstructured":"Raspa M, Bann CM, Gwaltney A, Benke TA, Fu C, Glaze DG, et al. A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials. Am J Intellect Dev Disabil. 2020;125(6):493\u2013509.","journal-title":"Am J Intellect Dev Disabil"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fnint.2020.00007","article-title":"Metabolic Signatures Differentiate Rett Syndrome From Unaffected Siblings","volume":"14","author":"Neul JL","year":"2020","unstructured":"Neul JL, Skinner SA, Annese F, Lane J, Heydemann P, Jones M, et al. Metabolic Signatures Differentiate Rett Syndrome From Unaffected Siblings. Front Integr Neurosci. 2020;14:7.","journal-title":"Front Integr Neurosci"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ana.26029","article-title":"Multisite Study of Evoked Potentials in Rett Syndrome","volume":"89","author":"Saby JN","year":"2021","unstructured":"Saby JN, Benke TA, Peters SU, Standridge SM, Matsuzaki J, Cutri-French C, et al. Multisite Study of Evoked Potentials in Rett Syndrome. Ann Neurol. 2021;89(4):790\u2013802.","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"105083","DOI":"10.1016\/j.nbd.2020.105083","article-title":"Detection of neurophysiological features in female R255X MeCP2 mutation mice","volume":"145","author":"Dong HW","year":"2020","unstructured":"Dong HW, Erickson K, Lee JR, Merritt J, Fu C, Neul JL. Detection of neurophysiological features in female R255X MeCP2 mutation mice. Neurobiol Dis. 2020;145:105083.","journal-title":"Neurobiol Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.irrdd.2022.05.001","article-title":"Psychometric perspectives on developmental outcome and endpoint selection in treatment trials for genetic conditions associated with neurodevelopmental disorder","volume":"62","author":"Farmer C","year":"2022","unstructured":"Farmer C, Kaat AJ, Berry-Kravis E, Thurm A. Psychometric perspectives on developmental outcome and endpoint selection in treatment trials for genetic conditions associated with neurodevelopmental disorder. Int Rev Res Dev Disa. 2022;62:1\u201339.","journal-title":"Int Rev Res Dev Disa"},{"key":"ref23","unstructured":"FDA. Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. Maryland, USA: FDA. ; 2018 [Available from: https:\/\/www.fda.gov\/media\/116276\/download."},{"key":"ref24","unstructured":"FDA. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders Maryland, USA: FDA. ; 2020 [Available from: https:\/\/www.fda.gov\/media\/139088\/download."},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10578-020-01051-z","article-title":"Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept Model","volume":"52","author":"Willgoss T","year":"2021","unstructured":"Willgoss T, Cassater D, Connor S, Krishnan ML, Miller MT, Dias-Barbosa C, et al. Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept Model. Child Psychiatry Hum Dev. 2021;52(4):654\u201368.","journal-title":"Child Psychiatry Hum Dev"},{"key":"ref26","author":"Weber JD","year":"2019","unstructured":"Weber JD, Smith E, Berry-Kravis E, Cadavid D, Hessl D, Erickson C. Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities.Brain Sci. 2019;9(2)."},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-021-01719-2","article-title":"Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale","volume":"16","author":"Patterson MC","year":"2021","unstructured":"Patterson MC, Lloyd-Price L, Guldberg C, Doll H, Burbridge C, Chladek M, et al. Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale. Orphanet J Rare Dis. 2021;16(1):79.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1866-1955-6-20","article-title":"Developmental delay in Rett syndrome: data from the natural history study","volume":"6","author":"Neul JL","year":"2014","unstructured":"Neul JL, Lane JB, Lee HS, Geerts S, Barrish JO, Annese F, et al. Developmental delay in Rett syndrome: data from the natural history study. J Neurodev Disord. 2014;6(1):20.","journal-title":"J Neurodev Disord"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/brain\/aww302","article-title":"Longitudinal course of epilepsy in Rett syndrome and related disorders","volume":"140","author":"Tarquinio DC","year":"2017","unstructured":"Tarquinio DC, Hou W, Berg A, Kaufmann WE, Lane JB, Skinner SA, et al. Longitudinal course of epilepsy in Rett syndrome and related disorders. Brain. 2017;140(2):306\u201318.","journal-title":"Brain"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"e2594","DOI":"10.1212\/WNL.0000000000007560","article-title":"Hand stereotypies: Lessons from the Rett Syndrome Natural History Study","volume":"92","author":"Stallworth JL","year":"2019","unstructured":"Stallworth JL, Dy ME, Buchanan CB, Chen CF, Scott AE, Glaze DG, et al. Hand stereotypies: Lessons from the Rett Syndrome Natural History Study. Neurology. 2019;92(22):e2594\u2013e603.","journal-title":"Neurology"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","article-title":"Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome","volume":"55","author":"Motil KJ","year":"2012","unstructured":"Motil KJ, Caeg E, Barrish JO, Geerts S, Lane JB, Percy AK, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr. 2012;55(3):292\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2018.03.010","article-title":"The course of awake breathing disturbances across the lifespan in Rett syndrome","volume":"40","author":"Tarquinio DC","year":"2018","unstructured":"Tarquinio DC, Hou W, Neul JL, Berkmen GK, Drummond J, Aronoff E, et al. The course of awake breathing disturbances across the lifespan in Rett syndrome. Brain Dev. 2018;40(7):515\u201329.","journal-title":"Brain Dev"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2788.2011.01404.x","article-title":"Social impairments in Rett syndrome: characteristics and relationship with clinical severity","volume":"56","author":"Kaufmann WE","year":"2011","unstructured":"Kaufmann WE, Tierney E, Rohde CA, Suarez-Pedraza MC, Clarke MA, Salorio CF, et al. Social impairments in Rett syndrome: characteristics and relationship with clinical severity. J Intellect Disabil Res. 2011;56(3):233\u201347.","journal-title":"J Intellect Disabil Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2019.03.017","article-title":"Severity Assessment in CDKL5 Deficiency Disorder","volume":"97","author":"Demarest S","year":"2019","unstructured":"Demarest S, Pestana-Knight EM, Olson HE, Downs J, Marsh ED, Kaufmann WE, et al. Severity Assessment in CDKL5 Deficiency Disorder. Pediatr Neurol. 2019;97:38\u201342.","journal-title":"Pediatr Neurol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fgene.2018.00635","article-title":"MECP2 Mutation Interrupts Nucleolin-mTOR-P70S6K Signaling in Rett Syndrome Patients","volume":"9","author":"Olson CO","year":"2018","unstructured":"Olson CO, Pejhan S, Kroft D, Sheikholeslami K, Fuss D, Buist M, et al. MECP2 Mutation Interrupts Nucleolin-mTOR-P70S6K Signaling in Rett Syndrome Patients. Front Genet. 2018;9:635.","journal-title":"Front Genet"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/jmedgenet-2017-104956","article-title":"Further delineation of the MECP2 duplication syndrome phenotype in 59 French male patients, with a particular focus on morphological and neurological features","volume":"55","author":"Miguet M","year":"2018","unstructured":"Miguet M, Faivre L, Amiel J, Nizon M, Touraine R, Prieur F, et al. Further delineation of the MECP2 duplication syndrome phenotype in 59 French male patients, with a particular focus on morphological and neurological features. J Med Genet. 2018;55(6):359\u201371.","journal-title":"J Med Genet"},{"key":"ref37","author":"Yang T","year":"2012","unstructured":"Yang T, Ramocki M, Neul JL, Lu W, Roberts L, Knight M et al. Immunodeficiency Due to Over-Expression of the Gene Encoding Methyl-CpG Binding Protein 2. Science Translational Medicine. 2012;in press."},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajmg.a.61956","article-title":"Phenotypic features in MECP2 duplication syndrome: Effects of age","volume":"185","author":"Peters SU","year":"2021","unstructured":"Peters SU, Fu C, Marsh ED, Benke TA, Suter B, Skinner SA, et al. Phenotypic features in MECP2 duplication syndrome: Effects of age. Am J Med Genet A. 2021;185(2):362\u20139.","journal-title":"Am J Med Genet A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"805745","DOI":"10.3389\/fneur.2021.805745","article-title":"Cortical Visual Impairment in CDKL5 Deficiency Disorder","volume":"12","author":"Quintiliani M","year":"2021","unstructured":"Quintiliani M, Ricci D, Petrianni M, Leone S, Orazi L, Amore F, et al. Cortical Visual Impairment in CDKL5 Deficiency Disorder. Front Neurol. 2021;12:805745.","journal-title":"Front Neurol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.neuroscience.2016.03.027","article-title":"Visual impairment in FOXG1-mutated individuals and mice","volume":"324","author":"Boggio EM","year":"2016","unstructured":"Boggio EM, Pancrazi L, Gennaro M, Lo Rizzo C, Mari F, Meloni I, et al. Visual impairment in FOXG1-mutated individuals and mice. Neuroscience. 2016;324:496\u2013508.","journal-title":"Neuroscience"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2566253\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2566253\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T15:28:13Z","timestamp":1697470093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2566253\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":40,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2566253\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s11689-023-09502-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,3,20]]},"subtype":"preprint"}}